title: Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
abstract: Patients with thyroid cancer are monitored for disease recurrence by measurement of serum thyroglobulin (Tg) and iodine-131 (131I) scanning. To enhance sensitivity and to circumvent antibodies that interfere with Tg immunoassays, we have developed RT-PCR assays that detect circulating thyroid messenger RNA (mRNA) transcripts. We now report results using a sensitive quantitative Tg mRNA assay (Taqman; ABI, Foster City, CA) in comparison with immunoassay in patients previously treated for thyroid cancer. We evaluated 107 patients: 84 during T4 therapy, 14 after T4 withdrawal, and 9 at both time points. All patients had near-total thyroidectomy, and 92% received postoperative 131I. Serum TSH, Tg protein, and Tg mRNA were measured. Patients were grouped based on most recent 131I scan or pathologically confirmed disease as having no detectable thyroid tissue (n = 33), thyroid bed uptake (n = 37), cervical/regional adenopathy (n = 21), or distant metastases (n = 16). During T4 therapy, median (range) Tg mRNA values (pg Tg Eq/microg thyroid RNA) for the groups were 1.5 (0-26.8), 9.4 (0.5-90.0), 15.4 (0.2-92), and 12.4 (1.9-16.6), respectively. Using a value of 3 pg Tg Eq/microg thyroid RNA as cut-point, Tg mRNA was positive in 38% of patients with no uptake, 75% with thyroid bed uptake, 84% with cervical/regional disease, and 94% with distant metastases. The median Tg mRNA value for patients with no uptake was lower than the median values for patients with thyroid bed uptake (P = 0.009) or with detectable thyroid tissue at any site (P = 0.010). Patients with negative 131I whole body scans were also less likely to have detectable Tg mRNA levels than were patients with thyroid bed uptake (P < 0.001) or any detectable thyroid tissue at any location (P < 0.001). Similar differences between these groups were seen after T4 withdrawal and for the 23 patients with circulating anti-Tg antibodies, when analyzed separately. Eight of the nine patients studied with low and high TSH concentrations displayed greater amounts of circulating Tg mRNA after T4 withdrawal. In three patients followed prospectively, the amount Tg mRNA correlated with the presence and absence of cervical metastases. In conclusion, we have demonstrated that a quantitative Tg mRNA assay can identify thyroid cancer patients with recurrent or residual thyroid tissue with greater sensitivity and similar specificity to Tg immunoassay during T4 therapy. The assay was unaffected by anti-Tg antibodies, responded to TSH-stimulation, and was reduced after surgical removal of metastases. These data suggest that this quantitative Tg mRNA assay may be a sensitive marker of tumor recurrence or response to therapy, particularly in patients with anti-Tg antibodies.
authors.affiliation: Department of Medicine, Washington Hospital Center and Medstar Research Institute, Washington, DC 20010, USA. mxr9@mhg.edu
authors.forename: M D
authors.initials: MD
authors.lastname: Ringel
authors.forename: P L
authors.initials: PL
authors.lastname: Balducci-Silano
authors.forename: J S
authors.initials: JS
authors.lastname: Anderson
authors.forename: C A
authors.initials: CA
authors.lastname: Spencer
authors.forename: J
authors.initials: J
authors.lastname: Silverman
authors.forename: Y H
authors.initials: YH
authors.lastname: Sparling
authors.forename: G L
authors.initials: GL
authors.lastname: Francis
authors.forename: K D
authors.initials: KD
authors.lastname: Burman
authors.forename: L
authors.initials: L
authors.lastname: Wartofsky
authors.forename: P W
authors.initials: PW
authors.lastname: Ladenson
authors.forename: M A
authors.initials: MA
authors.lastname: Levine
authors.forename: R M
authors.initials: RM
authors.lastname: Tuttle
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000097:blood / Q000000981:diagnostic imaging / Q000628:therapy; D001323:Autoantibodies / Q000097:blood; D002291:Carcinoma, Papillary / Q000097:blood / Q000000981:diagnostic imaging / Q000628:therapy; D005260:Female; D006801:Humans; D007118:Immunoassay; D007457:Iodine Radioisotopes; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis* / Q000000981:diagnostic imaging; D011446:Prospective Studies; D012333:RNA, Messenger / Q000097:blood*; D011877:Radionuclide Imaging; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D013954:Thyroglobulin / Q000097:blood / Q000235:genetics* / Q000276:immunology; D013964:Thyroid Neoplasms / Q000097:blood* / Q000000981:diagnostic imaging / Q000628:therapy; D013965:Thyroidectomy; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D001323:Autoantibodies; D007457:Iodine Radioisotopes; D012333:RNA, Messenger; D013972:Thyrotropin; D013954:Thyroglobulin; D013974:Thyroxine